Identification of Extended-Spectrum, AmpC, and Carbapenem- Hydrolyzing β-Lactamases in Escherichia coli and Klebsiella pneumoniae by Disk Tests

ABSTRACT Antibiotic disks with and without clavulanic acid, 3-aminophenylboronic acid, or EDTA were tested with a set of 55 Klebsiella pneumoniae and Escherichia coli strains producing well-characterized extended-spectrum, AmpC, or carbapenem-hydrolyzing β-lactamases. A relatively simple scheme was devised for distinguishing β-lactamase types in clinical isolates with or without intact outer membrane porins.

[1]  Clinical,et al.  Performance Standards for Antimicrobial Susceptibility Testing; Eighteenth Informational Supplement , 2008 .

[2]  A. Robicsek,et al.  qnrB, Another Plasmid-Mediated Gene for Quinolone Resistance , 2006, Antimicrobial Agents and Chemotherapy.

[3]  Mingzhi Wang,et al.  Plasmid-mediated quinolone resistance in clinical isolates of Escherichia coli , 2006 .

[4]  Robert A. Bonomo,et al.  Extended-Spectrum (cid:2) -Lactamases: a Clinical Update , 2005 .

[5]  J. Pitout,et al.  Evaluation of β-Lactamase Inhibitors in Disk Tests for Detection of Plasmid-Mediated AmpC β-Lactamases in Well-Characterized Clinical Strains of Klebsiella spp , 2005, Journal of Clinical Microbiology.

[6]  Y. Arakawa,et al.  Practical Methods Using Boronic Acid Compounds for Identification of Class C β-Lactamase-Producing Klebsiella pneumoniae and Escherichia coli , 2005, Journal of Clinical Microbiology.

[7]  G. Jacoby,et al.  The new beta-lactamases. , 2005, The New England journal of medicine.

[8]  Allison M. Land,et al.  Molecular Characterization of Cefoxitin-Resistant Escherichia coli from Canadian Hospitals , 2005, Antimicrobial Agents and Chemotherapy.

[9]  G. Paul,et al.  Dissemination in five French hospitals ofKlebsiella pneumoniae serotype K25 harbouring a new transferable enzymatic resistance to third generation cephalosporins and aztreonam , 1988, European Journal of Clinical Microbiology and Infectious Diseases.

[10]  Neil Woodford,et al.  Outbreak of Klebsiella pneumoniae Producing a New Carbapenem-Hydrolyzing Class A β-Lactamase, KPC-3, in a New York Medical Center , 2004, Antimicrobial Agents and Chemotherapy.

[11]  G. Jacoby,et al.  Epidemiology of Conjugative Plasmid-Mediated AmpC β-Lactamases in the United States , 2004, Antimicrobial Agents and Chemotherapy.

[12]  D. Yong,et al.  Evaluation of the Hodge Test and the Imipenem-EDTA Double-Disk Synergy Test for Differentiating Metallo-β-Lactamase-Producing Isolates of Pseudomonas spp. and Acinetobacter spp , 2003, Journal of Clinical Microbiology.

[13]  G. Jacoby,et al.  Plasmid-Mediated Quinolone Resistance in Clinical Isolates of Escherichia coli from Shanghai, China , 2003, Antimicrobial Agents and Chemotherapy.

[14]  G. Jacoby,et al.  Epidemiology of Extended-Spectrum β-Lactamases in Sofia, Bulgaria , 2003, European Journal of Clinical Microbiology and Infectious Diseases.

[15]  R. Goering,et al.  Plasmid-mediated, carbapenem-hydrolysing beta-lactamase, KPC-2, in Klebsiella pneumoniae isolates. , 2003, The Journal of antimicrobial chemotherapy.

[16]  G. Barnaud,et al.  Novel Plasmid-Encoded Class C β-Lactamase (MOX-2) in Klebsiella pneumoniae from Greece , 2002, Antimicrobial Agents and Chemotherapy.

[17]  A. Oliver,et al.  TEM-71, a Novel Plasmid-Encoded, Extended-Spectrum β-Lactamase Produced by a Clinical Isolate of Klebsiella pneumoniae , 2002, Antimicrobial Agents and Chemotherapy.

[18]  G. Jacoby,et al.  Evolution of TEM-Related Extended-Spectrum β-Lactamases in Korea , 2001, Antimicrobial Agents and Chemotherapy.

[19]  G. Jacoby,et al.  Identification of CTX-M-14 Extended-Spectrum β-Lactamase in Clinical Isolates of Shigella sonnei,Escherichia coli, and Klebsiella pneumoniae in Korea , 2001, Journal of Clinical Microbiology.

[20]  M. Ferraro.  Performance standards for antimicrobial susceptibility testing , 2001 .

[21]  A. Oliver,et al.  Molecular Characterization of FOX-4, a New AmpC-Type Plasmid-Mediated β-Lactamase from an Escherichia coli Strain Isolated in Spain , 2000, Antimicrobial Agents and Chemotherapy.

[22]  G. Jacoby,et al.  Characterization of the Extended-Spectrum β-Lactamase Reference Strain, Klebsiella pneumoniae K6 (ATCC 700603), Which Produces the Novel Enzyme SHV-18 , 2000, Antimicrobial Agents and Chemotherapy.

[23]  L. Martínez-Martínez,et al.  Relationship between outer membrane alterations and susceptibility to antimicrobial agents in isogenic strains of Klebsiella pneumoniae. , 2000, The Journal of antimicrobial chemotherapy.

[24]  J. Herrmann,et al.  Outbreak of Klebsiella pneumoniae producing transferable AmpC-type beta-lactamase (ACC-1) originating from Hafnia alvei. , 2000, FEMS microbiology letters.

[25]  Thierry Naas,et al.  Characterization of VIM-2, a Carbapenem-Hydrolyzing Metallo-β-Lactamase and Its Plasmid- and Integron-Borne Gene from a Pseudomonas aeruginosa Clinical Isolate in France , 2000, Antimicrobial Agents and Chemotherapy.

[26]  Y. Arakawa,et al.  Convenient Test for Screening Metallo-β-Lactamase-Producing Gram-Negative Bacteria by Using Thiol Compounds , 2000, Journal of Clinical Microbiology.

[27]  U. Ullmann,et al.  A Novel Type of AmpC β-Lactamase, ACC-1, Produced by a Klebsiella pneumoniae Strain Causing Nosocomial Pneumonia , 1999, Antimicrobial Agents and Chemotherapy.

[28]  G. Jacoby,et al.  Roles of β-Lactamases and Porins in Activities of Carbapenems and Cephalosporins against Klebsiella pneumoniae , 1999, Antimicrobial Agents and Chemotherapy.

[29]  G. Storch,et al.  CTX-M-5, a Novel Cefotaxime-Hydrolyzing β-Lactamase from an Outbreak of Salmonella typhimuriumin Latvia , 1998, Antimicrobial Agents and Chemotherapy.

[30]  P. Lagrange,et al.  Characterization of FOX-3, an AmpC-Type Plasmid-Mediated β-Lactamase from an Italian Isolate ofKlebsiella oxytoca , 1998, Antimicrobial Agents and Chemotherapy.

[31]  G. Jacoby,et al.  Detection of extended-spectrum beta-lactamases in clinical isolates of Klebsiella pneumoniae and Escherichia coli , 1996, Journal of clinical microbiology.

[32]  D. Livermore.  beta-Lactamases in laboratory and clinical resistance , 1995, Clinical microbiology reviews.

[33]  F. Baquero,et al.  Gene sequence and biochemical characterization of FOX-1 from Klebsiella pneumoniae, a new AmpC-type plasmid-mediated beta-lactamase with two molecular variants , 1994, Antimicrobial Agents and Chemotherapy.

[34]  A. Mentis,et al.  Identification of a novel plasmid-mediated beta-lactamase with chromosomal cephalosporinase characteristics from Klebsiella pneumoniae. , 1993, The Journal of antimicrobial chemotherapy.

[35]  S. Ichiyama,et al.  Plasmid-mediated AmpC-type beta-lactamase isolated from Klebsiella pneumoniae confers resistance to broad-spectrum beta-lactams, including moxalactam , 1993, Antimicrobial Agents and Chemotherapy.

[36]  R. Labia,et al.  Identification of CTX-2, a novel cefotaximase from a Salmonella mbandaka isolate , 1991, Antimicrobial Agents and Chemotherapy.

[37]  A. Philippon,et al.  Novel transferable extended-spectrum beta-lactamase (SHV-6) from Klebsiella pneumoniae conferring selective resistance to ceftazidime. , 1991, FEMS microbiology letters.

[38]  G. Papanicolaou,et al.  Novel plasmid-mediated beta-lactamase (MIR-1) conferring resistance to oxyimino- and alpha-methoxy beta-lactams in clinical isolates of Klebsiella pneumoniae , 1990, Antimicrobial Agents and Chemotherapy.

[39]  G. Papanicolaou,et al.  Outbreak of ceftazidime resistance caused by extended-spectrum beta-lactamases at a Massachusetts chronic-care facility , 1990, Antimicrobial Agents and Chemotherapy.

[40]  A. Philippon,et al.  Two novel transferable extended-spectrum beta-lactamases from Klebsiella pneumoniae in Tunisia. , 1990, FEMS microbiology letters.

[41]  S. Cole,et al.  Molecular characterization of the gene encoding SHV-3 beta-lactamase responsible for transferable cefotaxime resistance in clinical isolates of Klebsiella pneumoniae , 1989, Antimicrobial Agents and Chemotherapy.

[42]  R. Cluzel,et al.  Multiplicity of TEM-derived beta-lactamases from Klebsiella pneumoniae strains isolated at the same hospital and relationships between the responsible plasmids , 1989, Antimicrobial Agents and Chemotherapy.

[43]  G. Paul,et al.  TEM-4, a new plasmid-mediated beta-lactamase that hydrolyzes broad-spectrum cephalosporins in a clinical isolate of Escherichia coli , 1989, Antimicrobial Agents and Chemotherapy.

[44]  G. Verschraegen,et al.  Plasmid-mediated beta-lactamases in clinical isolates of Klebsiella pneumoniae and Escherichia coli resistant to ceftazidime , 1989, Antimicrobial Agents and Chemotherapy.

[45]  G. Jacoby,et al.  Broad-spectrum, transmissible beta-lactamases. , 1988, The New England journal of medicine.

[46]  J. Carlet,et al.  Plasmid-mediated beta-lactamase (TEM-7) involved in resistance to ceftazidime and aztreonam. , 1988, Reviews of infectious diseases.

[47]  R. Cluzel,et al.  Novel plasmid-mediated beta-lactamase in clinical isolates of Klebsiella pneumoniae more resistant to ceftazidime than to other broad-spectrum cephalosporins , 1988, Antimicrobial Agents and Chemotherapy.

[48]  R. Spencer,et al.  Novel β-lactamase in a clinical isolate of Klebsiella pneumoniae conferring unusual resistance to β-lactam antibiotics , 1987 .